
    
      The study will consist of 4 parts: 1) an initial Monotherapy Dose Escalation part, 2) a
      Combination Dose Escalation part, 3) a Pharmacokinetic (PK) Evaluation part, and 4) a diffuse
      large B-cell lymphoma (DLBCL) Expansion part.
    
  